Discovery Labs DSCO and FDA Meeting Results

September 30, 2009 - Shares of Discovery Laboratories, Inc (DSCO) are spiking in pre market this morning after the company and the FDA have established a path for potential Surfaxin FDA Approval. DSCO stock is indicated to open Up 55% to $1.72 in early trading.

DSCO Forum

Discovery Labs and FDA Establish Path for Potential Surfaxin Approval

Discovery Laboratories, Inc. (Nasdaq:DSCO) held a teleconference on September 29, 2009 with the U.S. Food and Drug Administration (FDA). The meeting established an approach to potentially resolve the remaining primary issue that Discovery Labs must address to gain U.S. marketing approval of Surfaxin(R) (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants. The meeting focused on Discovery Labs' plans regarding optimization and final method validation of its fetal rabbit Biological Activity Test (BAT, a quality control and stability release test) and a proposed limited Surfaxin clinical trial design, which would simultaneously employ the newly-optimized BAT. Full Article

Looking at the chart, there is major resistance located at $2 and $2.40. If DSCO stock was to close over $2.40 at any time in the future, the next major resistance level would be $3.02. I will be buying DSCO if it breaks $2.00.

Today's Biggest Stock Market Gainers - Top 2009 Stock Gainers - Top 2009 Penny Stocks

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free

Discovery Laboratories DSCO FDA 9/29/09

Don't forget - Discovery Laboratories Inc. (DSCO) is expected to meet with the FDA September 29, 2009 on marketing approval for lung cancer drug Surfaxin. Expect the stock to be active before and after this meeting.


Discovery Laboratories, Inc. (Nasdaq:DSCO) has received written notification from the U.S. Food and Drug Administration (FDA) that a meeting has been scheduled for September 29, 2009. This meeting will serve as a follow-up to the June 2 meeting with the FDA and the FDA’s April 17 Complete Response letter. The objective of this meeting is to define the options available to Discovery Labs to resolve the remaining primary issue that Discovery Labs must address to gain U.S. marketing approval of Surfaxin® (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants.

At the upcoming September 29 meeting, Discovery Labs plans to discuss with the FDA a limited Surfaxin clinical trial design and whether conducting such trial, while simultaneously employing the fetal rabbit Biological Activity Test (BAT, a quality control and stability release test), could potentially address the key remaining requirement for Surfaxin approval. This approach was suggested by the FDA at the June 2 meeting as a way for Discovery Labs to increase the likelihood of gaining Surfaxin approval. In addition, Discovery Labs plans to review its ongoing quality improvement efforts, intended to further refine the BAT in accordance with Discovery Labs’ continuing quality improvement initiatives, with the FDA.

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free